Revefenacin: Difference between revisions

Jump to navigation Jump to search
Line 26: Line 26:


==Use in Specific Populations==
==Use in Specific Populations==
*Revefencin is not affected majorly by age, weight, or gender
*Hepatic impariment has not been studied to see if there are necessary precautions to take
*Patients with renal impariment
**Mesure for antimuscarinic adverse events or the inhibitting of acetocholine, a neurotransmitter in the PNS


==IV Compatibility==
==IV Compatibility==

Revision as of 04:16, 8 October 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]

Overview

Adult Indications and Dosage

  • The agreed dosage is 175 micrograms per day
    • Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
    • Makes it easy for patients with pulmonary problems

Pediatric Indications and Dosage

Contradictions

Hypersensitivity under any ingredient in Revefenacin

Warnings

Adverse Reactions

Side Effects

  • Headache
  • Cough
  • Problems regarding the upper respiratory system
  • Back Pain

Drug Interactions

  • Revefenacin and active metabolite (when drug is metabolized by the body into a modified form) are not affected severely smoking status

Use in Specific Populations

  • Revefencin is not affected majorly by age, weight, or gender
  • Hepatic impariment has not been studied to see if there are necessary precautions to take
  • Patients with renal impariment
    • Mesure for antimuscarinic adverse events or the inhibitting of acetocholine, a neurotransmitter in the PNS

IV Compatibility

  • Intravenous solution in healthy volunteers
    • Volume of distribution was 218 L
    • Intravenous solution radioactivity:
    • 54% came out as solid waste
    • 27% came out as liquid waste

Pharmacology

See Clinical Studies

Clinical Studies

Trials:

  • Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
  • 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)

Pharmacology trials:

  • Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans
    • Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs
    • This drug attacked "mAChRs mediated contractile responses"
    • This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans

Conclusion:

  • Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD

How is it supplied

  • Given to patients via jet nebulizer

Patient Counseling Information

  • Currently Running a 52 week phase three trial for patients with severe OCPD

Precautions with Alcohol

There is limited information on Alcohol-Revefencin interactions. Talk to your doctor for further instruction on consuming alcohol with Revefenacin.

Brand Names

  • Yupelri